Integrative Cancer Therapies最新文献

{"title":"Survey of United States Ayurvedic Medicine Professionals Regarding Their Work With People With Cancer.","authors":"Oluwadamilola Olaku, Anand A Dhruva, Gabriel Lopez, Bhaswati Bhattacharya, Manohar S Gundeti, Julia T Arnold, Anupama Kizhakkeveettil, Benmei Liu, Frank J Ninivaggi, Sophia M King, Jeffrey D White","doi":"10.1177/15347354261495562","DOIUrl":"https://doi.org/10.1177/15347354261495562","url":null,"abstract":"<p><p>PurposeAyurveda, a Traditional Indian Medicine practice, supports health and is used by trained professionals in the United States (US). However, little is known about their opinions and practices. This study explored the use of Ayurveda in managing individuals with cancer in the US.MethodsA questionnaire was developed to assess experiences and opinions of Ayurvedic medicine professionals caring for individuals with cancer in the US and was administered online using Microsoft Forms. The survey utilized a convenience sample of Ayurvedic medicine professionals.ResultsOf 321 participants, 199 had treated US individuals with cancer and continued the survey. Most (94%) held an Ayurvedic certification, 12% had an additional non-Ayurvedic medical degree, and 55% had a healthcare-related license. Over half (55%) managed/counseled individuals with cancer. Respondents indicated that individuals with cancer sought Ayurveda primarily to reduce allopathic treatment-related side effects (87%). Eighty-five percent of respondents recommended herbs for individuals with cancer in the US, though some herbs were also considered contraindicated. Most (65%) \"never/rarely\" or \"occasionally\" communicated with patients' allopathic doctors.ConclusionThis report is the first to document the opinions and practices of Ayurvedic professionals managing people with cancer in the US. Respondents noted limited communication and research collaboration with biomedical communities, despite interest in doing so. More research on Ayurveda's adjunctive role in cancer care is needed to define its place in Integrative Oncology. Improved education and communication between Ayurvedic and biomedical communities are essential for individuals with cancer safety and outcomes.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261495562"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Systematic Review and Meta-Analysis.","authors":"Khadija Panhwar, Shiza Rizwan, Muhammad Bilal Khan, Diksha Ladhani, Rachna Katyara, Bibi Zarfeen Talpur, Nouraiz Abbas, Archita Archita, Fatima Laique, Bibek Giri","doi":"10.1177/15347354261490585","DOIUrl":"10.1177/15347354261490585","url":null,"abstract":"<p><p>BackgroundBreast cancer (BRCA) remains the most diagnosed malignancy among women globally and is predominantly managed through multimodal therapy. Radiotherapy, an essential component of BRCA management, often causes fatigue, anxiety, and depression that compromise the quality of life (QoL) of patients. Melatonin, an endogenous hormone with antioxidant, anti-inflammatory, and circadian rhythm-modulating properties, has shown potential for preventing radiotherapy-associated toxicities. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of melatonin in alleviating radiotherapy-induced fatigue, anxiety, and depression among breast cancer patients.MethodsFollowing PRISMA guidelines (PROSPERO: CRD420251144916), a comprehensive search was conducted across PubMed, Scopus, Cochrane Library, Embase, and Google Scholar up to August 2025. RCTSs comparing melatonin with placebo in adult female patients with non-metastatic breast cancer undergoing adjuvant radiotherapy were included. The Cochrane RoB-2 tool was employed for quality assessment. Pooled standardized mean differences (SMDs) and mean differences (MDs) were calculated using a random-effects model in RevMan 5.4 software.ResultsFive RCTs encompassing 561 patients were analyzed. Melatonin significantly reduced fatigue severity (SMD = -0.43; 95% CI -0.65 to -0.20; p = 0.0002) and improved cognitive functioning (MD = 1.16; 95% CI 0.95 to 1.36; p < 0.00001) and global health status (MD = 2.47; 95% CI 2.07 to 2.87; p < 0.00001). No significant effects were observed for emotional, social, or physical functioning, nor for gastrointestinal, pain, or sleep-related domains.ConclusionBased on limited number of studies, melatonin supplementation appears to be a safe, well-tolerated, and low-cost adjunct to radiotherapy, capable of improving fatigue, cognitive performance, and overall QoL in breast cancer patients. However, small sample sizes and heterogeneous dosing regimens require further large-scale RCTs to establish optimal dosing and long-term efficacy.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261490585"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor Regarding \"Efficacy of Herbal Medicine Therapy Combined with Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis\".","authors":"Dong-Hyeon Kim, Keon-Jun Lee, So-Jung Park","doi":"10.1177/15347354261443179","DOIUrl":"10.1177/15347354261443179","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261443179"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ayurveda in Integrative Oncology: Aligning Traditional Principles with Conventional Cancer Care.","authors":"S Narayanan, K Desai, S Ravani, R Puthiyedath, H Newton, E Ben-Arye, R Panse, S Rao, A Dhruva, J T Arnold","doi":"10.1177/15347354261499374","DOIUrl":"https://doi.org/10.1177/15347354261499374","url":null,"abstract":"<p><p>Patients challenged with cancer diagnosis and treatments often seek solutions beyond conventional therapies to improve their quality of life and immunity and to manage symptoms, concerns, coping, and daily functioning. Ayurveda, a traditional medical system originating in India, has generated growing interest within integrative oncology; however, limited clarity and evidence exist regarding its appropriate application and integration across the oncology care continuum. This paper explores the evolving landscape of integrative oncology, focusing on the incorporation of Ayurveda into global cancer care. With emphasis on evidence-based practices, we discuss the similarities and distinctions between Ayurvedic and integrative oncology approaches including nutrition, exercise, mind body practices, sleep, and use of herbal supplements. We aim to stimulate further dialogue and multidisciplinary collaboration between oncology healthcare providers and Ayurveda clinicians. Developing a patient-centered, evidence-informed, integrative model of care that incorporates Ayurvedic approaches has the potential to enhance the quality of life for patients along the cancer trajectory. This discussion may stimulate further research and medical education with the goal of incorporating supported Ayurvedic approaches into mainstream cancer care.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261499374"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to the Editor Regarding \"Efficacy of Chinese Medicine on Postoperative Rehabilitation of Non-Small Cell Lung Cancer (NSCLC), a Randomized Controlled Study\" in Integrative Cancer Therapies.","authors":"Yifeng Gu, Yichao Wang, Huiling Zhou, Ao Qi, Guanjin Wu, Jiaqi Li, Jialin Yao, Wenxiao Yang, Lingzi Su, Yi Liu, Xueqi Tian, Jiajun Song, Yabin Gong, Lijing Jiao, Ling Xu, Congmeng Zhang, Yong Yang, Xiong Qin","doi":"10.1177/15347354251408741","DOIUrl":"10.1177/15347354251408741","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251408741"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12901889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis.","authors":"Sarah Benna-Doyle, Suzanne Grant, Alison Maunder, Jing Liu, Melik Ibrahim, Adele Cave, Chhiti Pandey, Monica Tang, Eng-Siew Koh, Geoff Delaney, Deep Jyoti Bhuyan, Victoria Choi, Ki Kwon, Maria Gonzalez, Susannah Graham, Ashanya Malalasekera, Carolyn Ee","doi":"10.1177/15347354251405267","DOIUrl":"10.1177/15347354251405267","url":null,"abstract":"<p><p>Cancer survivors experience a range of side effects during and after treatment. There is a need for a rigorous synthesis of the most recent and best available evidence on the role of nutritional supplements for supportive care in cancer, to inform shared decision-making. We searched 5 databases for umbrella reviews, meta-analyses and systematic reviews on nutritional supplements for supportive cancer care, excluding studies on pain, anxiety and depression, which are covered in recent guidelines. We found 52 reviews that reported on 250 RCTs on 18 supplements for 16 indications. Almost all reviews were of low/critically low quality (assessed using A MeaSurement Tool to Assess systematic Reviews version 2). There was moderate-certainty evidence for benefit from the following supplements: amino acids and oral proteolytic enzymes for severity of radiation-induced dermatitis, N-acetyl cysteine for prevention of chemotherapy-induced peripheral neuropathy (CIPN) in individuals with gastrointestinal cancers. There was low to very low certainty evidence that glutamine, zinc, probiotics and melatonin may be effective for oral mucositis; Vitamin E, omega-3 fatty acids, glutamine and other amino acids may be effective for preventing CIPN. Serious adverse events were reported for high-dose Vitamin A, and dose-related adverse events were reported with zinc and Vitamin E. However, the majority of nutritional supplements were associated with only minor adverse events. Due to the low to very low certainty of the majority of evidence, firm clinical recommendations cannot be made. Further research to conclusively evaluate benefit and harm, including potential impact on efficacy of standard treatments, should be conducted.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251405267"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12764759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.","authors":"Ya-Dong Chen, Zi-Yan He, Wen-Jie Zhao, Yi-Han He, Yi-Hong Liu, Yan-Juan Zhu, Ya-Ya Yu, Zhen-Zhen Xiao, Xue-Song Chang, Zong-Bin Liu, Hai-Bo Zhang","doi":"10.1177/15347354251396002","DOIUrl":"10.1177/15347354251396002","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer is one of the most common and fatal cancers worldwide. Despite therapeutic advancements, patients with stage II and III colon cancer often experience recurrences and metastases, particularly to the liver, leading to suboptimal disease-free survival (DFS) rates and decreased long-term survival. Qu-Shi-Jie-Du decoction (QSJDD), a traditional Chinese herbal formula, may prevent cancer recurrence and spread by boosting immunity, reducing inflammation, and inhibiting tumour growth. Preliminary studies have demonstrated that QSJDD reduces liver metastasis in patients with colon cancer. However, robust clinical evidence is required to confirm its efficacy and safety.</p><p><strong>Objective: </strong>This study aims to evaluate the safety and efficacy of QSJDD in preventing colon cancer recurrence and liver metastasis, thereby offering a potential adjunctive therapy to improve patient outcomes.</p><p><strong>Methods: </strong>This multicentre, double-blind, randomised, placebo-controlled trial involves 336 high-risk stage II or III colon cancer patients from 10 Chinese hospitals. Post-surgery and chemotherapy, 168 patients will receive either QSJDD compound granules or a placebo for 6 months, with a 3-year follow-up and evaluations every 6 months. The primary endpoint is to measure the 3-year DFS rate, while secondary endpoints include 1- and 2-year DFS rates, overall survival, and changes in the Traditional Chinese Medicine Dampness Syndrome Scale. Safety and adverse events will be tracked, and blood and gut microbiomes will be analysed to assess QSJDD's impact on delaying colon cancer metastasis.</p><p><strong>Discussion: </strong>This trial will determine the efficacy and safety of QSJDD and provide evidence regarding its role in the adjuvant treatment of colon cancer.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251396002"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preference of Traditional Chinese Medicine Service Utilization Among Cancer Patients in China: A Discrete Choice Experiment.","authors":"Ruyue Liu, Junyi Ji, Baoyang Ding, Nan Zhang, Qiang Sun","doi":"10.1177/15347354261492302","DOIUrl":"https://doi.org/10.1177/15347354261492302","url":null,"abstract":"<p><p>Traditional Chinese medicine (TCM) has demonstrated potential benefits in cancer treatment, yet its relatively low utilization may limit the realization of these benefits. This study aimed to explore cancer patients' preferences for TCM services and assess how various service characteristics influence their utilization. A discrete choice experiment was conducted among 500 cancer patients aged 18-75 years. Each patient completed nine choice tasks, each involving two hypothetical TCM service alternatives characterized by five attributes: service institution, care provider, type of treatment, risk of side effects, and monthly cost. A mixed logit model was used to estimate patients' preferences, willingness to pay and predicted utilization. In total, 469 patients (93.8%) completed the questionnaire. All five attributes significantly influenced patients' preferences. Service institution had the greatest impact on TCM utilization (importance score, 47.59%), followed by care provider and type of treatment. Changing the service setting from a TCM clinic to a cancer hospital or a general hospital would increase the predicted utilization of TCM services by 87.60% and 69.20%, respectively. Gender, age, annual family income, cancer stage, and family history of cancer were also associated with TCM utilization. Cancer patients generally had positive attitudes toward TCM services. Service institution was the primary driver of TCM utilization, whereas monthly cost was the least important factor. These findings provide policymakers and healthcare professionals with valuable insights into the effective integration of TCM as an adjunct to cancer treatment, with the potential to improve patient care.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261492302"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Photobiomodulation in Treatment of Head and Neck Cancer-Related Chronic Lymphedema: A Pilot Randomized Controlled Trial.","authors":"Jie Deng, John N Lukens, Barbara A Murphy, Erin McMenamin, Karthik Rajasekaran, Ryan J Quinn, Joy C Cohn, Wendy Schlessinger, Lucy P Andersen, Bryan A Spinelli, Alexander Lin","doi":"10.1177/15347354261439138","DOIUrl":"10.1177/15347354261439138","url":null,"abstract":"<p><strong>Background: </strong>Chronic lymphedema is a common late effect after completion of head and neck cancer (HNC) treatment, contributing to substantial symptom burden and negatively impacting quality of life. No effective approaches are available to treat this progressive condition. This study aimed to evaluate the preliminary efficacy of photobiomodulation (PBM) therapy for chronic lymphedema in HNC survivors.</p><p><strong>Methods: </strong>This was a pilot, randomized, wait-list controlled trial. Eligible HNC survivors included those with chronic lymphedema after completion of complete decongestive therapy. Participants were randomized (1:1) to 1 of 2 arms: intervention group (active) or wait-list control group (control). The active group received 12 PBM therapy sessions (twice a week for 6 weeks). The control group completed the study assessments and was then offered the same dose of PBM therapy as the active group. Lymphedema and fibrosis (LEF), symptom burden, jaw range of motion, and neck range of motion were measured at baseline, end-of-intervention, 4-week, and 8-week post-intervention.</p><p><strong>Results: </strong>Twenty five HNC survivors were randomized to the active group (n = 12) and the control group (n = 13). About 91.7% planned PBM treatment sessions were completed. No adverse events were reported. Compared to the control group, the active group demonstrated improvements at 8-week post-intervention in the severity of external LEF (<i>P</i> < .001), symptom burden (eg, Soft Tissue and Neurologic Toxicity subscale, Cohen's <i>d</i> = - 0.47), and neck range of motion (eg, extension, Cohen's <i>d</i> = 0.65).</p><p><strong>Conclusion: </strong>PBM therapy may improve chronic lymphedema-associated outcomes. Future large randomized controlled trials are warranted to examine the efficacy of PBM therapy for HNC-related chronic lymphedema.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261439138"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Feasibility Study of Reiki Therapy to Improve Symptoms in Cancer Survivors at an Integrative Oncology Clinic.","authors":"Natalie L Dyer, Karen E Fink, Shashwat Chakraborti, Jesse Cheng, Jeffery A Dusek, Santosh Rao","doi":"10.1177/15347354261467711","DOIUrl":"10.1177/15347354261467711","url":null,"abstract":"<p><p>The purpose of this pilot study was to examine the feasibility and acceptability of Reiki therapy for cancer survivors with moderate-to-severe symptom clusters. Adult patients with a neoplasm diagnosis, not currently undergoing active treatment, and reporting a fatigue score of ≥ 4 and two other symptoms were eligible to participate. The intervention was six 30-45-minute Reiki sessions within 6-8 weeks. The Edmonton Symptom Assessment System (ESAS-9) was completed pre- and post-Reiki session. Quality of life (PROMIS-29) measures were completed at baseline and 8 weeks after the first Reiki session. As a pilot feasibility study, recruitment, retention, attendance, data completeness, and acceptability were the focus. Descriptive statistics were generated for ESAS and PROMIS data, but no hypothesis testing was done. Twenty-three patients were pre-screened and ten were eligible, enrolled in the study, and completed baseline measures. Nine signed up for Reiki and six of those participants completed the intervention and follow-up measures (67%). All participants were female and non-Hispanic, 70% were White, 20% were African American/Black, and 10% were multiracial. Participants attended an average of 5.5 Reiki sessions. Outcome data completeness was 100%. Numerical improvements in all symptom scores and quality of life domains after Reiki were observed. Participants were overall satisfied with the Reiki. This pilot study of Reiki for cancer survivors demonstrated satisfactory feasibility. Highly preliminary assessment of outcome measures revealed sensitivity to change following Reiki. This study provides support to proceed with more research; however, modifications are needed before conducting a fully powered randomized controlled trial.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261467711"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13354905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}